Category: Other Policy Priorities (Page 3)

March 27, 2015

FY16 AFib Appropriations Sign-On Letter

The Alliance for Aging Research signed onto a letter requesting the National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), National Institute of Neurological Disorders and Stroke (NINDS), and other relevant NIH agencies, institutes, and offices provide technical assistance and otherwise support an effort to improve prevention of AFib-related stroke in older persons.
March 4, 2015

Alliance Offers Comment on FDA Testosterone Prescription Labeling Communication

We wanted to share our reaction to communication from the U.S. Food and Drug Administration regarding updates to the labeling of prescription testosterone products.
March 4, 2015

Medicare Part D Non-Interference Letter

The Alliance for Aging Research signed a letter expressing opposition to proposals that would allow the Secretary of Health and Human Services (HHS) to interfere in private prescription drug negotiations in the Medicare Part D program.
February 6, 2015

Con. Res. Supporting Quality of Life for Prostate Cancer Patients Support Letter

The Alliance for Aging Researched signed on to a Urology Policy Forum (UPF) letter expressing support for Con. Res., the Supporting Quality of Life for Prostate Cancer Patients. 
January 15, 2015

Alliance Takes Part in Hill Briefing on Medicare Advantage

Yesterday the Alliance had the privilege of participating in a Capitol Hill briefing hosted by the Coalition for Medicare Choices (CMC) on the value of Medicare Advantage.
January 14, 2015

The Medicare Advantage Experience: Perspectives from Providers and Beneficiaries

The Coalition for Medicare Choices (CMC) invites you to a briefing to hear from providers, health care stakeholders, and members of the coalition about why Medicare Advantage is such a critical choice for nearly 16 million Americans who rely on it.
September 17, 2013

One Year Later: FDASIA and its Impact for Diseases of Aging

Join us for One Year Later: FDASIA and its Impact for Diseases of Aging.
May 13, 2013

Tweets Do Tell: Alzhemier’s Not a High Priority for Research Funding

An article by Cynthia Bens, Alliance vice president of public policy
September 28, 2012

AHRQ Submitted Comments on Key Questions for Stroke Prevention in Atrial Fibrillation–2012

September 28, 2012 Agency for Health Research and Quality Effective Health Care Program Scientific Resource Center, Oregon EPC…
September 4, 2012

PQRS Submitted Comments on Proposed Rule for Revisions to the 2013 Medicare Physician Fee Schedule

September 4, 2012 Marilyn Tavenner Acting Administrator  Centers for Medicare & Medicaid Services Department of Health and Human Services Attn: CMS-1590-P P.O. Box 8013 Baltimore, MD 21244-8013  RE: Comments on Proposed Rule for Revisions to the 2013 Medicare Physician Fee Schedule Dear Administrator Tavenner: Because of the growing impact atrial fibrillation (AFib) is having on our aging population, the AFib Optimal Treatment Task Force, comprised of 12 leading organizations in the thrombosis space, formed in 2011 to raise awareness of the impact of the disease and to explore issues related to the process used by healthcare providers to assess both stroke and bleeding risk in making decisions about anticoagulation therapy for patients with AFib. We appreciate the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) Proposed Rule for Revisions to the 2013 Medicare Physician Fee Schedule. Our comments on the proposed rule will be limited to a new measure #1525, Chronic Anticoagulation Therapy, which is under consideration by CMS for inclusion in the Physician Quality Reporting System (PQRS) for CY2013. Recent expert consensus led by the AFib Optimal Treatment Task Force supports the use of this measure but with an additional recommendation to encourage routine and proper bleeding risk assessment. We urge you to include a modified version of measure #1525 in the final rule that encourages a bleeding risk assessment in addition to a stroke risk assessment to ensure that Medicare beneficiaries with AFib are presented with all treatment options that may be available for them.